Human Leukocyte Antigen – DR isotype (HLA-DR) (HLA-DR)

The HLA-DR peptide-binding groove is a critical structural domain of the Human Leukocyte Antigen – DR isotype (HLA-DR), a Major Histocompatibility Complex (MHC) class II receptor primarily expressed on professional antigen-presenting cells such as dendritic cells, B cells, and macrophages (1.1.2, 1.5.2). This "open-ended" groove is formed by the heterodimerization of alpha and beta chains and is responsible for binding and presenting exogenous peptide fragments, typically 12 to 26 amino acids in length, to CD4+ T-cell receptors (1.3.3, 1.4.3). This interaction is the fundamental step in initiating and regulating adaptive immune responses and maintaining self-tolerance (1.1.2, 1.5.3). In various autoimmune conditions, such as multiple sclerosis and rheumatoid arthritis, the HLA-DR groove inappropriately presents self-antigens, triggering a pathogenic immune response (1.3.2, 1.5.1). Consequently, the groove is a major therapeutic target; drugs like glatiramer acetate work by competitively binding to the groove, thereby preventing the presentation of autoantigens and shifting the immune response toward a more regulatory, anti-inflammatory state (1.2.1, 1.2.4). Furthermore, the groove is a site of idiosyncratic drug interactions, where certain small molecules can bind and alter the repertoire of presented peptides, leading to severe hypersensitivity reactions (1.1.1, 1.4.2).

Other names

HLA-DR peptide-binding grooveMHC class II DR peptide-binding cleftHLA-DR antigen-binding grooveHLA-DR PBRHuman leukocyte antigen DRMajor histocompatibility complex class II DR

Drugs targeting the HLA-DR peptide-binding groove primarily act through competitive inhibition, where they bind to the groove with high affinity to displace or prevent the binding of pathogenic autoantigens (1.2.3, 1.2.4). This competition can lead to immune deviation, shifting the T-cell response from a pro-inflammatory Th1/Th17 phenotype to an anti-inflammatory Th2 or regulatory T-cell (Treg) phenotype (1.2.1, 1.2.5). Additionally, some small molecules can bind to the groove and alter the conformation of the HLA-peptide complex, creating neoantigens that trigger idiosyncratic hypersensitivity reactions (1.1.1, 1.4.2).